Form 4: Organon CHRO Aaron Falcione Executes RSU Transactions
Statement of Changes in Beneficial Ownership
Organon & Co. Chief Human Resources Officer Aaron Falcione reported the vesting of restricted stock units and a new grant of 166,944 units.
Summary
- Aaron Falcione, Chief Human Resources Officer at Organon & Co., reported the vesting of 17,925 restricted stock units (RSUs) on March 31, 2026.
- A total of 6,140 shares were withheld to cover tax obligations at a price of $5.70 per share.
- The reporting person received a new grant of 166,944 RSUs, which are scheduled to vest in three equal annual installments starting March 31, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine executive compensation and tax compliance.
Positives
- The executive maintains a significant equity stake in the company, totaling 101,431.071 shares following the transactions.
- The new RSU grant aligns the executive's long-term incentives with shareholder interests through a three-year vesting schedule.
Negatives
- The transaction involved the withholding of 6,140 shares to satisfy tax liabilities, which is a standard but routine reduction in direct holdings.
Risks
- The value of the equity compensation is subject to market volatility, as evidenced by the tax withholding price of $5.70 per share.
Future Outlook
The reporting person holds 166,944 unvested RSUs that will vest in equal installments on March 31, 2027, 2028, and 2029, contingent upon continued service.
Management Comments
- The filing does not contain narrative management commentary.
Industry Context
StockSavvy.ai notes that this filing represents standard executive compensation activity within the pharmaceutical sector, where equity-based incentives are primary tools for talent retention.
Comparison to Industry Standards
- The use of three-year graded vesting for RSU grants is consistent with standard corporate governance practices for executive compensation in the U.S. pharmaceutical industry.
- Tax withholding at the time of vesting is a standard administrative procedure for equity plans at companies like Pfizer or Merck.
Stakeholder Impact
- Minimal impact on shareholders as these are standard equity compensation transactions.
Next Steps
- Vesting of the first installment of the new RSU grant on March 31, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Original grant date of 20,195 RSUs. |
| 03/31/2025 | Original grant date of 33,579 RSUs. |
| 03/30/2026 | Closing market price date used for tax withholding calculation. |
| 03/31/2026 | Transaction date for RSU vesting and new grant. |
| 04/02/2026 | Filing date of the Form 4. |
| 03/31/2027 | First vesting date for the new 166,944 RSU grant. |
Keywords
Organon, OGN, Insider Trading, Form 4, Equity Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.